181 related articles for article (PubMed ID: 33220655)
1. Low serum Α-SYNUCLEIN and oligomer Α-SYNUCLEIN levels in multiple sclerosis patients.
Bilge N; Simsek F; Yevgi R; Ceylan M; Askın S
J Neuroimmunol; 2020 Nov; 350():577432. PubMed ID: 33220655
[TBL] [Abstract][Full Text] [Related]
2. Detection of α-synuclein oligomers in red blood cells as a potential biomarker of Parkinson's disease.
Wang X; Yu S; Li F; Feng T
Neurosci Lett; 2015 Jul; 599():115-9. PubMed ID: 25998655
[TBL] [Abstract][Full Text] [Related]
3. Tumor necrosis factor-alfa and interleukin-4 in cerbrospinal fluid and plasma in different clinical forms of multiple sclerosis.
Obradović D; Kataranovski M; Dincić E; Obradović S; Colić M
Vojnosanit Pregl; 2012 Feb; 69(2):151-6. PubMed ID: 22500369
[TBL] [Abstract][Full Text] [Related]
4. Low levels of alpha-synuclein in peripheral tissues are related to clinical relapse in relapsing-remitting multiple sclerosis: a pilot cross-sectional study.
Mejía M; Rodríguez-Leyva I; Cortés-Enríquez F; Chi-Ahumada E; Portales-Pérez DP; Macías-Islas MA; Jiménez-Capdeville ME
J Neurol Sci; 2019 Jan; 396():87-93. PubMed ID: 30445232
[TBL] [Abstract][Full Text] [Related]
5. Mitoxantrone: a review of its use in multiple sclerosis.
Scott LJ; Figgitt DP
CNS Drugs; 2004; 18(6):379-96. PubMed ID: 15089110
[TBL] [Abstract][Full Text] [Related]
6. Estimation of Alpha-Synuclein Monomer and Oligomer Levels in the Saliva of the Children With Autism Spectrum Disorder: A Possibility for an Early Diagnosis.
Siddique A; Khan HF; Ali S; Abdullah A; Munir H; Ariff M
Cureus; 2020 Aug; 12(8):e9936. PubMed ID: 32968597
[TBL] [Abstract][Full Text] [Related]
7. Decreased levels of alpha-synuclein in cerebrospinal fluid of patients with clinically isolated syndrome and multiple sclerosis.
Antonelou RCh; Emmanouilidou E; Gasparinatos G; Velona T; Voumvourakis KI; Stefanis L
J Neurochem; 2015 Aug; 134(4):748-55. PubMed ID: 25962981
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of Alpha-Synuclein Cerebrospinal Fluid Levels in Several Neurological Disorders.
Agnello L; Lo Sasso B; Vidali M; Scazzone C; Gambino CM; Piccoli T; Bivona G; Ciaccio AM; Giglio RV; La Bella V; Ciaccio M
J Clin Med; 2022 May; 11(11):. PubMed ID: 35683523
[TBL] [Abstract][Full Text] [Related]
9. A Prospective Study to Evaluate the Possible Role of Cholecalciferol Supplementation on Autoimmunity in Hashimoto's Thyroiditis.
Bhakat B; Pal J; Das S; Charaborty SK; SircarMedical NR; Kolkata ; RGKar ; NorthBengal ; Siliguri
J Assoc Physicians India; 2023 Jan; 71(1):1. PubMed ID: 37116030
[TBL] [Abstract][Full Text] [Related]
10. Glial and neuroaxonal biomarkers in a multiple sclerosis (MS) cohort.
Kalatha T; Hatzifilippou E; Arnaoutoglou M; Balogiannis S; Koutsouraki E
Hell J Nucl Med; 2019; 22 Suppl 2():113-121. PubMed ID: 31802051
[TBL] [Abstract][Full Text] [Related]
11. [Alterations in erythrocytic oligomeric alpha-synuclein in patients with Parkinson's disease and multiple system atrophy].
Yan XM; Li PJ; Li W; Wang XM; Yu S
Zhonghua Yi Xue Za Zhi; 2023 Oct; 103(37):2933-2939. PubMed ID: 37752052
[No Abstract] [Full Text] [Related]
12. Serum α-synuclein and IL-1β are increased and correlated with measures of disease severity in children with epilepsy: potential prognostic biomarkers?
Choi J; Kim SY; Kim H; Lim BC; Hwang H; Chae JH; Kim KJ; Oh S; Kim EY; Shin JS
BMC Neurol; 2020 Mar; 20(1):85. PubMed ID: 32151248
[TBL] [Abstract][Full Text] [Related]
13. LC-MS/MS assay for the investigation of acetylated Alpha-synuclein in serum from postmortem Alzheimer's disease pathology.
Uchida K; Morikawa K; Muguruma Y; Hosokawa M; Tsutsumiuchi K; Kaneda D; Hashizume Y; Akatsu H; Inoue K
J Chromatogr B Analyt Technol Biomed Life Sci; 2021 Sep; 1181():122885. PubMed ID: 34479181
[TBL] [Abstract][Full Text] [Related]
14. Cerebrospinal fluid and plasma distribution of anti-α-synuclein IgMs and IgGs in multiple system atrophy and Parkinson's disease.
Folke J; Rydbirk R; Løkkegaard A; Hejl AM; Winge K; Starhof C; Salvesen L; Pedersen LØ; Aznar S; Pakkenberg B; Brudek T
Parkinsonism Relat Disord; 2021 Jun; 87():98-104. PubMed ID: 34020303
[TBL] [Abstract][Full Text] [Related]
15. Intrathecal IgM index correlates with a severe disease course in multiple sclerosis: Clinical and MRI results.
Ozakbas S; Cinar BP; Özcelik P; Baser H; Kosehasanoğullari G
Clin Neurol Neurosurg; 2017 Sep; 160():27-29. PubMed ID: 28622533
[TBL] [Abstract][Full Text] [Related]
16. CXCL10 and CXCL13 chemokines in patients with relapsing remitting and primary progressive multiple sclerosis.
Iwanowski P; Losy J; Kramer L; Wójcicka M; Kaufman E
J Neurol Sci; 2017 Sep; 380():22-26. PubMed ID: 28870573
[TBL] [Abstract][Full Text] [Related]
17. Cardiac Alpha-Synuclein Is Present in Alpha-Synucleinopathies.
Javanshiri K; Drakenberg T; Haglund M; Englund E
J Parkinsons Dis; 2022; 12(4):1125-1131. PubMed ID: 35275559
[TBL] [Abstract][Full Text] [Related]
18. α-Synuclein oligomers induce early axonal dysfunction in human iPSC-based models of synucleinopathies.
Prots I; Grosch J; Brazdis RM; Simmnacher K; Veber V; Havlicek S; Hannappel C; Krach F; Krumbiegel M; Schütz O; Reis A; Wrasidlo W; Galasko DR; Groemer TW; Masliah E; Schlötzer-Schrehardt U; Xiang W; Winkler J; Winner B
Proc Natl Acad Sci U S A; 2018 Jul; 115(30):7813-7818. PubMed ID: 29991596
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of the Adherence to Immunmodulatory Treatment in Patients with Multiple Sclerosis.
Köşkderelioğlu A; Gedizlioğlu M; Ortan P; Öcek Ö
Noro Psikiyatr Ars; 2015 Dec; 52(4):376-379. PubMed ID: 28360743
[TBL] [Abstract][Full Text] [Related]
20. The good and bad of therapeutic strategies that directly target α-synuclein.
Longhena F; Faustini G; Brembati V; Pizzi M; Bellucci A
IUBMB Life; 2020 Apr; 72(4):590-600. PubMed ID: 31693290
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
